Clostridium Difficile Toxin A Antibody (5155)

Product Discontinued

Clostridium Difficile Toxin A Antibody (5155) Summary

• Immunogen: Clostridium Difficile Toxin A
• Specificity: This product is specific for Clostridium difficile toxin A. No reaction is observed with the following organisms:Clostridium difficile toxin B, tetanus toxoid, Pseudomonas aeruginosa and Yersinia enterocolitica Clostridium difficile is a gram-positive motile bacterium which is the leading cause of diarrhoea in developed countries. The incidence of disease in humans varies greatly with age, spore density and the administration of antibiotics. Toxin A (TcdA) is a large exotoxin which is an essential virulence factor for C. difficile infection. TcdA has a molecular weight of 308kD and is a glucosyltransferase, which irreversibly inactivates the Ras family of small GTPases to disrupt many important signalling pathways.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity: Tissue culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA 1:20-1:200
  • Western Blot
• Application Notes: Use in Western blot reported in scientific literature (PMID: 29735765).

Reactivity Notes

Reacts with Bacteria.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.09% Sodium Azide
• Concentration: This product is unpurified. The exact concentration of antibody is not quantifiable.
• Purity: Tissue culture supernatant

Alternate Names for Clostridium Difficile Toxin A Antibody (5155)

• TcdA
• ToxA
• Toxin A

Background

Clostridia are toxin-producing anaerobic bacteria that cause a number of serious diseases, including tetanus, botulism, and tissue infections. Clostridia normally inhabit the human intestinal tract, soil, and decaying vegetation. All species of clostridia produce toxins. Some clostridial diseases, such as botulism and the various diarrheal illnesses, result solely from the toxin without any bacterial invasion of tissue. In other clostridial diseases, such as tetanus and clostridial wound infections, there is both tissue invasion and toxin production. This antibody detects Clostridium difficile, a gram-positive motile bacterium which is the leading cause of diarrhoea in developed countries. The incidence of disease in humans varies greatly with age, spore density, and the administration of antibiotics. Toxin A (TcdA) is a large exotoxin which is an essential virulence factor for C. difficile infection. TcdA has a molecular weight of 308kD and is a glucosyltransferase, which irreversibly inactivates the Ras family of small GTPases to disrupt many important signalling pathways.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Clostridium Difficile Toxin A Antibody (NB100-62471)(1)

Publication using NB100-62471

• Anjuwon-Foster BR, Maldonado-Vazquez N, Tamayo R. Et al. Characterization of Flagellum and Toxin Phase Variation in Clostridioides difficile Ribotype 012 Isolates J Bacteriol 2018-05-09 [PMID: 29735765] (WB, Bacteria)
  
  Details:
  Citation using the DyLight 800 version of this antibody.

Review for Clostridium Difficile Toxin A Antibody (NB100-62471) (1)

Average Rating: 1

(Based on 1 review)

We have 1 review tested in 1 species: Clostridium difficile.

reviewed by: Verified Customer WB Clostridium difficile 05/16/2017

Summary

• Application: Western Blot
• Sample Tested: Bacterial lysates and TCA-precipitated supernatant
• Species: Clostridium difficile
• Lot: 0

FAQs for Clostridium Difficile Toxin A Antibody (NB100-62471). (Showing 1 - 1 of 1 FAQ).

1. I am seeking monoclonal antibodies specific for the C Terminal binding regions of clostridum difficile toxins A and B (aa1852-2366)?
   • I would recommend catalog # NB100-62473. Although it is a polyclonal, it is the only one that we know binds to the C-Terminal portion of the protein. The other antibodies we have against both targets are synthesized from the full length sequence. We do not routinely epitope map our antibodies so we cannot be certain where they are binding. This polyclonal is synthesized against a small 10 amino acid region of the protein so it should be highly specific to that location.